ArriVent BioPharma (AVBP) Other Operating Expenses (2024 - 2026)

ArriVent BioPharma has disclosed Other Operating Expenses across 3 years of filings, most recently posting -$2.3 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$2.3 million, down 7.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.9 million (down 17.2% YoY), and the FY2025 annual result was -$8.8 million, down 22.77% from the prior year.
• Other Operating Expenses came in at -$2.3 million for Q1 2026 at ArriVent BioPharma, down from -$2.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of -$1.5 million in Q4 2024 to a low of -$2.4 million in Q2 2025.
• The 3-year median for Other Operating Expenses is -$2.1 million (2024), against an average of -$2.0 million.
• Peak annual rise in Other Operating Expenses reached 7.37% in 2025, while the deepest fall reached 54.86% in 2025.
• ArriVent BioPharma's Other Operating Expenses stood at -$1.5 million in 2024, then slumped by 54.86% to -$2.3 million in 2025, then retreated by 2.21% to -$2.3 million in 2026.
• The last three Other Operating Expenses figures came in at -$2.3 million (Q1 2026), -$2.3 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.